Alpha 2.0
Login Register
» Authors » G E Verhoef

G E Verhoef

Explore the profile of G E Verhoef including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 40
Citations 461
Followers 0
Related Specialties
Hematology
Oncology
General Surgery
Top 10 Co-Authors
M A Boogaerts
H Demuynck
P Zachee
P Vandenberghe
B Lowenberg
E Vellenga
H Van Den Berghe
G J Ossenkoppele
L F Verdonck
C De Wolf-Peeters
Published In
Ann Hematol
Br J Haematol
Leukemia
Bone Marrow Transplant
Cancer Genet Cytogenet
Affiliations
Soon will be listed here.
Recent Articles
1.
Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia
Devriendt K, Kim A, Mathijs G, Frints S, Schwartz M, van den Oord J, et al.
Nat Genet . 2001 Mar; 27(3):313-7. PMID: 11242115
The Wiskott-Aldrich syndrome protein (WASP; encoded by the gene WAS) and its homologs are important regulators of the actin cytoskeleton, mediating communication between Rho-family GTPases and the actin nucleation/crosslinking factor,...
2.
P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia
van der Kolk D, De Vries E, van Putten W, Verdonck L, Ossenkoppele G, Verhoef G, et al.
Clin Cancer Res . 2000 Aug; 6(8):3205-14. PMID: 10955805
Despite treatment with intensive chemotherapy, a considerable number of patients with acute myeloid leukemia (AML) die from their disease due to the occurrence of resistance. Overexpression of the transporter proteins...
3.
Disseminated infection by Scedosporium prolificans: an emerging fatality among haematology patients. Case report and review
Maertens J, Lagrou K, Deweerdt H, Surmont I, Verhoef G, Verhaegen J, et al.
Ann Hematol . 2000 Jul; 79(6):340-4. PMID: 10901616
We describe a case of proven disseminated infection by Scedosporium prolificans in a profoundly neutropenic patient. The patient presented with a fever unresponsive to broad-spectrum antibiotics, endophthalmitis, respiratory failure and...
4.
Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests
Janssen J, van Rijn R, van der Holt B, Schuurhuis G, Vellenga E, Verhoef G, et al.
Bone Marrow Transplant . 2000 Jun; 25(11):1147-55. PMID: 10849527
We collected peripheral blood stem cells (PBSC) in 19 early chronic phase CML patients following each of two consecutive cycles of intensive chemotherapy (CT) to evaluate whether an additional cycle...
5.
Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis
Maertens J, Demuynck H, Verbeken E, Zachee P, Verhoef G, Vandenberghe P, et al.
Bone Marrow Transplant . 1999 Aug; 24(3):307-12. PMID: 10455371
In a 10-year consecutive series of 263 allogeneic bone marrow transplant recipients, we identified five cases (1.9%) of invasive mucormycosis. Only one infection occurred within the first 100 days after...
6.
A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group
Ossenkoppele G, van der Holt B, Verhoef G, Daenen S, Verdonck L, Sonneveld P, et al.
Leukemia . 1999 Aug; 13(8):1207-13. PMID: 10450748
The purpose of this study was to determine the safety and efficacy of filgrastim as an adjunct to induction and consolidation chemotherapy in poor risk patients with myelodysplastic syndrome (MDS)....
7.
Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?
Vellenga E, van Putten W, Boogaerts M, Daenen S, Verhoef G, Hagenbeek A, et al.
Bone Marrow Transplant . 1999 Jul; 23(12):1279-82. PMID: 10414916
The clinical use of autologous marrow transplantation in acute myeloid leukemia (AML) has been hampered by the inability to collect adequate numbers of cells after remission induction chemotherapy and the...
8.
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma
Segeren C, Sonneveld P, van der Holt B, Baars J, Biesma D, Cornellissen J, et al.
Br J Haematol . 1999 May; 105(1):127-30. PMID: 10233375
We examined the feasibility of achieving a rapid response in patients with previously untreated multiple myeloma by administering vincristine 0.4 mg and doxorubicin 9 mg/m2 as a rapid intravenous infusion...
9.
Lymphocyte profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: flow-cytometric characterization and analysis in a two-dimensional correlation biplot
Van den Hove L, Meeus P, Derom A, Demuynck H, Verhoef G, Vandenberghe P, et al.
Ann Hematol . 1998 Aug; 76(6):249-56. PMID: 9692812
The distribution of 27 T-, B-, and natural killer-cell subsets in the peripheral blood of 40 patients with multiple myeloma (MM), ten patients with monoclonal gammopathy of undetermined significance (MGUS),...
10.
Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment
Van den Hove L, Vandenberghe P, Van Gool S, Ceuppens J, Demuynck H, Verhoef G, et al.
Leuk Res . 1998 May; 22(2):175-84. PMID: 9593474
Flow cytometry immunophenotyping of peripheral blood lymphocyte subsets and multivariate data-analytical techniques revealed that among untreated hemato-oncological patients (n = 48) with lymphomas, acute and chronic myeloid and lymphocytic leukemias,...